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ABSTRACT
Liver metastases from gastric cancer (LMGC) is a non-curable, fatal disease with a 5-year survival rate of <10%.
Although various local treatments have been applied, their clinical utility has not been established. The purpose
of this study was to investigate the safety and effectiveness of proton beam therapy (PBT) for the treatment of
patients with LMGC. A total of nine patients (seven men, two women; aged 56–78 years) with LMGC who
received PBT between 2002 and 2012 were retrospectively reviewed. Patients who had tumors conﬁned to the
liver were investigated, and patients who had extrahepatic tumors were excluded. Six of the patients had solitary
tumors, and three patients had multiple tumors. The total irradiation dose was 64–77 Gy relative biological
effectiveness (RBE), and three patients received concurrent chemotherapy. The overall and progression-free sur-
vival (OS and PFS) rates, local control (LC) rate, and adverse effects were investigated. All patients completed
treatment without interruption, and late adverse effects of higher than Grade 3 were not observed. The OS rates
at 1, 3 and 5 years were 100%, 78% and 56%, respectively (median, 5.5 years); the PFS rates were 67%, 40%
and 40% (median, 2.6 years); and the LC rates were 89%, 71% and 71%. PBT was demonstrated to be a safe
treatment, and the OS and PFS rates were not inferior to those for other types of local treatment. Therefore,
PBT should be considered as an effective local treatment option for patients with LMGC.
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INTRODUCTION
Gastric cancer is one of the most common malignancies worldwide.
Liver metastasis can be found in 5–14% of patients with gastric can-
cer [1–4]. Most patients with liver metastases from gastric cancer
(LMGC) have bilobar multinodular tumors, and the cancer recur-
rence and metastatic patterns are associated with locoregional peri-
toneal dissemination and with diffuse metastases to the lymph
nodes. The vast majority of patients with LMGC may in fact have
systemic disease. Only a very small number of patients with LMGC
are candidates for local treatment [5].
Although systemic chemotherapy with new molecular targeting
agents has been developed, LMGC is a non-curable, fatal disease
with a 5-year survival rate of <10%, and the management of liver
metastasis remains challenging. Thus, the treatment of patients with
LMGC is regarded as palliative. To improve the treatment outcome,
various local treatments such as surgery, radiofrequent ablation
(RFA), and transcatheter arterial chemoembolization (TACE) have
been applied, in combination with chemotherapy or as an alterna-
tive to chemotherapy [6]. However, the clinical utility of local treat-
ment for LMGC has not been established.
Proton beam therapy (PBT) has the physical characteristic of pre-
cisely delivering a high dose of radiation to the target tumor, while
greatly limiting the exposure to the regions beyond the target. It is
well known that PBT for primary liver cancer achieves excellent local
control (LC) rates with few adverse effects [7–11]. Moreover, we
previously investigated the effectiveness of PBT to metastatic liver
tumors although that study included various primary cancers and dis-
ease conditions [12]. The adaptations in the use of PBT for each
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disease type were yet to be clariﬁed, because radiosensitivity and the
aim of treatment differs among various types of primary cancers and
disease conditions. In this study we reviewed patients with LMGC who
received PBT, and investigated the safety and effectiveness of the PBT.
MATERIALS AND METHODS
Patients
We retrospectively investigated nine patients with LMGC who
received PBT at the University of Tsukuba between 2002 and 2012.
They comprised seven men and two women and had a median age
of 71 years (range, 56–78 years). The patients’ tumors could be
categorized as solitary tumors or as multiple tumors that could be
included within a few irradiation ﬁelds. Patients who had extrahepa-
tic tumors were excluded.
All patients had previously received curative surgery for the pri-
mary tumors. The duration from gastric surgery to PBT was 7–113
months (median, 36 months), and that from onset of liver metastasis
to PBT was 1–30 months (median, 6 months). Of the nine patients,
six had solitary tumors, and the remaining three, multiple tumors (2,
4 and >10). The maximal diameter of the tumors was 2–6 cm
(median, 3 cm). Eight of the patients had received another form of
treatment before the PBT, such as chemotherapy and TACE. Three
patients received concurrent chemotherapy (cisplatin/5-ﬂuorouracil
(5-FU), 5-FU, or tegafur/gimeracil/oteracil). According to the
Eastern Cooperative Oncology Group Performance Status (PS) scale,
all patients had a PS of 0 to 1 and a Child–Pugh score of 5 (class A).
The follow-up period after PBT was 1.2–11 years (median, 4.5 years).
The treatment strategy was discussed with surgeons or medical oncol-
ogists on an individual basis, considering the patient’s PS, tumor
location, and tumor size, and was approved at the in-hospital confer-
ence. The reasons for selection of PBT were as follows: incurability of
the cancer by chemotherapy (eight patients), inoperability of the can-
cer (three of those eight patients), and strong demand for PBT by
the patient (the one remaining patient). Written informed consent
was obtained from all the patients before the PBT, and analyses were
carried out with the approval of the Institutional Review Board. The
characteristics of the patients and of the tumors are shown in Table 1.
Proton beam therapy
Each patient’s body was immobilized using a custom-made body
cast. Computed tomography (CT) images were taken at 5-mm inter-
vals during the expiratory phase under a respiratory gating system
[13]. At the treatment planning stage, an aperture margin of 5–10
mm, a depth margin of 5–10 mm, and a margin of 5 mm on the cau-
dal axes were added to cover the entire clinical target volume to
compensate for uncertainty resulting from respiration-induced hep-
atic movements. These margins included the ﬁeld margins. A bolus
was fabricated for the smearing process. Proton beams from 155–
250MeV, generated through a linear accelerator and synchrotron,
were spread out and shaped with ridge ﬁlters, double-scattering
sheets, multicollimators, and custom-made boluses to ensure that the
beams conformed to the treatment planning data.
The proton beam therapy dose and fractionation were decided
according to the tumor location and the treatment strategy. As many
tumors as possible were included within the same irradiation ﬁeld, and
all three patients with multiple tumors (one: unilateral, two: bilat-
eral lobes) were treated with two irradiation ﬁelds. The total irradi-
ation dose was 64–77 (median, 72.6) Gy relative biological
Table 1. Summary of patients
Case Age/sex Number Distribution Size (cm) Dose Gy
(RBE)/fr
Precedent
therapy
Concurrent
therapy
Adjuvant
therapy
Survival period
(years)
1 69/F S Uni 2 72.6/22 C N N 11.0
2 76/F S Uni 4 72.6/22 C C N 8.4
3 61/M M Uni 6 70/35 C N N 6.4
66/10
4 77/M S Uni 2 66/10 N C C 5.5
5 77/M S Uni 4 72.6/22 C N C 4.5
6 71/M M Bi 5 72.6/22 C N N 3.8
72.6/22
7 78/M s Uni 2 64/32 C N C 3.0
8 56/M S Uni 3 72.6/22 C N N 2.3
9 59/M M Bi 2 77/35 C C C 1.2
66/10
S = solitary, M = multiple, Uni = unilateral lobe, Bi = bilateral lobes, C = chemotherapy, N = none. Underlining indicates the cases who are still alive at the ﬁnal
follow-up (April–June 2016).
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effectiveness (RBE). The most frequent dosage was 72.6 Gy (RBE)
in 22 fractions, used in six patients, followed by 66 Gy (RBE) in 10
fractions, used in three patients. The maximum cumulative dose was
set below 50 Gy (RBE) for the spinal cord, stomach and duodenum
and below 60 Gy (RBE) for the colon. The RBE of the PBT was
assumed to be 1.1 [14].
Treatment after PBT
Four patients received adjuvant chemotherapy after PBT. Moreover,
four patients received additional treatment to new or recurrent
tumors (PBT in two patients and chemotherapy in two patients).
Follow-up procedures and evaluation criteria
During the treatment sessions, acute treatment-related toxicities were
assessed weekly in all patients. After completion of the PBT, the
patients were evaluated by means of physical examinations, blood
tests, and CT or magnetic resonance imaging scans. Assessment of
response was evaluated according to the Response Evaluation Criteria
in Solid Tumors (version 1.1) [15]. We deﬁned local failure as an
increase in the maximal diameter of the treated target tumors of
>20% and of >5 mm. Adverse events were assessed after every pro-
cedure according to the Common Terminology Criteria for Adverse
Effects (CTCAE; version 4.03) [16]. The patients treated before
2010 were also retrospectively reviewed using the CTCAE.
For examination of safety, the treatment completion rate, liver tox-
icity, and late adverse effects were examined. For examination of the
treatment effect, the overall survival (OS), progression-free survival
(PFS) and LC rates were calculated using the Kaplan–Meier method.
RESULTS
Three of eight patients already had multiple tumors in the liver and
thus were obliged to undergo two-ﬁeld irradiation, and ﬁve patients
were treated with a single irradiation ﬁeld. All patients completed
the treatment without interruption. The biologically effective dose
for the liver (α/β = 3) was minimum: 10.0, maximum: 29.8 and
median: 12.5 Gy (RBE), and the volume that received >30 Gy (RBE)
(V30) was minimum: 12%, maximum: 42% and median: 20.7% of the
liver. Late adverse effects of higher than Grade 3 were not observed.
Of the nine patients, two were still alive at the ﬁnal follow-up
between April and June 2016. Local recurrence was observed in two
patients who had multiple tumors (two and four, respectively) in bilat-
eral lobes. In the former patient, local recurrence was observed 2.6 years
later, and the patient received additional PBT to the recurrent tumor;
he then survived 3.8 years from the ﬁrst PBT (Case 6 in Table 1). In
the latter patient, local recurrence and para aortic lymph node metasta-
ses were observed 3.3 months later; he then died 1.2 years later from
the PBT (Case 9). The OS rates at 1, 3 and 5 years were 100%, 78%
and 56%, respectively, with a median of 5.5 years; the PFS rates were
67%, 40% and 40%, with a median of 2.6 years; and the LC rates were
89%, 71% and 71% (Fig. 1). Acute dermatitis was Grade 1–2 in all
patients. Radiation-induced liver damage was not observed; nor were
severe adverse effects of more than Grade 3. No patient showed a
Child–Pugh score elevation of >2 during the follow-up.
Figure 2 shows a 77-year-old male patient with LMGC. He had
a solitary tumor in the S2 region. He received PBT at a dose of
72.6 Gy (RBE) in 22 fractions. CT 3.8 years after the PBT showed
a scar and atrophic change without recurrence. As at April 2016, he
is still alive 4.5 years after the PBT.
DISCUSSION
Reports on the local treatment of patients with LMGC are
extremely rare. For surgically treated patients, the OS rates at 1, 3
and 5 years were 62–79, 17–41 and 10–39%, with a median of
0.9–2.6 years [17–20]. For RFA-treated patients, the OS rates were
70–73, 5–43 and 3–34% [20, 21]. Moreover, some researchers
Fig. 1. (a) OS and PFS rates for all patients. (b) LC rates for all patients.
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reported using combined therapy such as surgery, RFA and micro-
wave coagulation therapy or various local treatment methods. The
outcomes of the local treatment for patients with LMGC in terms
of the OS rates were 62–87, 17–51 and 10–42% at 1, 3 and 5 years,
respectively, with a median of 0.4–3.4 years, and in terms of the
PFS rates were 48–57, 25–37 and 14–33%, with a median of 0.8–1
year [5, 17–23] (Table 2). Although severe adverse effects are rare,
Gunner et al. reported that 12 of 68 patients (18%) suffered severe
adverse effects of more than Grade 3 and that one patient died of
hepatic insufﬁciency on postoperative Day 19 [20]. The only case
study in which PBT combined with concurrent chemotherapy was
used was that reported by Gohongi et al.: their patient survived
>2 years without severe adverse effects [24].
As shown above, the OS rates at 1, 3 and 5 years in our study
using PBT were 100%, 78% and 56%, respectively, with a median of
5.5 years; the PFS rates were 67%, 40% and 40%, with a median of
2.6 years. In our study, seven of nine patients had oligometastasis,
whereas in the previous studies mentioned above, only one report
treated oligometastasis [19]; others were treated regardless of the
number of tumors. It was difﬁcult to compare our results with those
of previous studies unless the number of tumors corresponded.
Therefore, we compared our data with that of all previous reports
in which the tumor number, size and distribution were comparable
with those in our study. Our OS and PFS rates were not inferior to
those of the previous studies. Only four patients received regular
chemotherapy after PBT (paclitaxel: two, tegafur/gimeracil/osteracil:
two), and no patients received advanced chemotherapy because
most of the patients were initially chemo-resistant. In addition, local
recurrence was observed in two of the ﬁve patients who did not
receive adjuvant chemotherapy and also in two of the four patients
who received adjuvant chemotherapy. PFS includes both local PFS
and distant PFS. We consider that a high LC rate could directly
avoid a PFS rate reduction. Severe acute or late adverse effects or
radiation-induced liver damage was not observed. In view of the
poor outcome for the patients with LMGC (a 5-year OS rate of
<10% after chemotherapy), PBT is a safe and effective treatment
option if the metastasis is conﬁned to the liver.
The advantages of PBT for LMGC are as follows: (i) few
adverse effects, (ii) high LC rates, (iii) repeatable treatment and
(iv) the possibility of treatment for large tumors.
First, the tolerance doses for treatment of the liver have been
well documented. Austin-Seymour et al. reported the tolerance dose
as 30–35 Gy to one-third of the liver volume [25], and Emami et al.
reported that the 5% risk at 5 years was 30 Gy to the entire liver
[26]. The V30 was 12–42% in our patients. Even in the three
patients who had multiple tumors, the V30 was 42%, 20% and 21%
(which are tolerable values according to Emami’s criteria), and the
changes in the Child–Pugh score were 5 to 5, 5 to 6, and 5 to 5 dur-
ing follow-up, respectively (Cases 3, 5, 6). It is well established that
PBT has the distinct advantage of causing relatively little damage to
the healthy liver tissue in the treatment of primary liver cancers [7,
9, 27, 28]. Complicated hepatitis or liver cirrhosis is obviously less
frequent in patients with gastric cancer than in those with primary
liver cancer. From the data obtained in our study, in which no
patients showed a Child–Pugh score elevation of >2 during the
follow-up, and from the data regarding the safety obtained in the pre-
vious studies of primary liver cancers [7, 9, 27, 28], we consider that
the amount of liver toxicity following PBT was extremely small when
used for the treatment of LMGC. We concluded that the low level
of adverse effects is the best advantage of PBT for LMGC, compared
with surgery or systematic chemotherapy.
Second, we previously reported that the LC rates at 1, 3 and 5
years after PBT for primary liver cancers were 98%, 87% and 81%,
respectively. It seems that the LC rate for LMGC is not as high as
that for primary liver cancers because gastric cancer is not particu-
larly radiosensitive. However, in situations for which no other useful
treatment exists, we consider that PBT can play a role in local treat-
ment, given our data of LC rates of 71% at 5 years.
Third, gastric cancer can cause additional metastatic tumors, and
some of them might occur in the liver. Kakeji et al. reported that
the high recurrence rate within 2 years of surgery might suggest the
presence of occult intrahepatic metastases at the surgery and that
recurrence tumors usually develop in the liver after surgery
(62–79%) [6]. It is highly possible that additional local treatment
will be required for new metastatic tumors in gastric cancer patients.
Fig. 2. A 77-year-old male patient with LMGC. (a) Solitary
tumor with a 4-cm diameter in S2 (arrow) was irradiated
with PBT at a dose of 72.6 Gy (RBE)/22 fractions with the
patient in the prone position. Isodose lines represent, from
the inside to the outside, 95% to 10% of the dose at the
isocenter. (b) CT 3.8 years after PBT. The arrow indicates
the scar and atrophic change.
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In our study, three patients received concurrent two-ﬁeld PBT and
two patients received additional PBT when new liver metastases
appeared. Repeated PBT to the liver is sometimes experienced in
primary liver cancers, and its safety is sufﬁciently proven [29]. The
most important factors for determining repeated PBT are the ori-
ginal liver function and the accumulated irradiation dose. We try to
manage proton beam delivery so as not to overlap the previous pro-
ton beam paths and to leave >500 ml of the liver volume unirra-
diated as much as possible in daily clinical practice. Surgery is one
of the options for local treatment. However, repeated surgery can
be difﬁcult because of adhesions or complications, and it can be
unacceptable in many patients. Considering the success of repeated
PBT for primary liver cancers and the lower frequency of compli-
cated liver disease mentioned above, PBT should be an effective
and safe option in repeated treatment.
Fourth, RFA, which is another local treatment option in terms
of safety and repeatability, is limited to tumors of <5 cm in diam-
eter. PBT can be used to treat much larger tumors without severe
adverse effects. In our institute, the maximal tumor size that can be
treated is 15 × 15 cm length × width, 12 cm depth. In our study,
two patients had tumors >5 cm. Those patients survived 3.8 and
6.4 years, respectively. While smaller tumors can be controlled as
effectively using PBT as using RFA, larger tumors can be treated
with far less unnecessary irradiation to the liver.
For patients with LMGC, chemotherapy is the ﬁrst choice.
However, the treatment outcome for chemotherapy is not satisfactory.
If the metastatic tumors are conﬁned to the liver, several treatment
options have been performed, and some of them can achieve higher
OS rates than can conventional chemotherapy, even though evidence-
rich data for such higher OS rates do not exist. Our study was a retro-
spective one, and the number of patients was small. To determine the
total dose and fractionation for each disease type was difﬁcult; thus,
we used the same irradiation protocol as that used for primary liver
cancers. The equivalent dose (α/β = 10) of the two tumors that
showed recurrence was 80.1 Gy (RBE) [77 Gy (RBE) in 35 fractions]
and 91.5 Gy (RBE) [72.6 Gy (RBE) in 22 fractions]. On the other
hand, three tumors that were irradiated with 66 Gy (RBE) in 10 frac-
tions [equivalent dose: 126.7 Gy (RBE)] were controlled. Considering
the conventional irradiation dose is ~70 Gy (RBE) for most cancers,
an equivalent dose >90 Gy (RBE) would be necessary for radio-
resistant gastric cancers. However, the number of the patients in this
study was not large enough to determine the adequate dose fraction-
ation; further study with a larger number of patients is necessary.
Moreover, concurrent therapy could improve the treatment effect of
radio-resistant gastric cancer.
To the best of our knowledge, only one similar case report has
been published; ours is the ﬁrst report of multiple patients with
LMGC who have undergone PBT. The OS and PFS rates were not
inferior to those of other local treatments, and these data are similar
to those of previous studies of liver tumors [7–12, 27]. We con-
cluded that PBT is an effective local treatment option for LMGC.
High OS and PFS and LC rates comparable with that of surgery
indicate it would be a good second choice when inoperable tumors
are conﬁned to the liver. Unfortunately, we only have the data for
nine patients. We are considering further investigation with a great
number of patients to provide more detailed information on PBT
for patients with LMGC.
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